Retatrutide and Liver Fat: Triple Agonist Data
MASH and Peptide Therapies
86%
At 48 weeks, 86% of participants on retatrutide 12 mg achieved a relative liver fat reduction, with 93% reaching normal liver fat levels below 5%.
Sanyal et al., Nature Medicine, 2024
Sanyal et al., Nature Medicine, 2024
View as imageRetatrutide is a triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. In a phase 2a substudy, it reduced liver fat by up to 86% at 48 weeks, with 93% of participants on the highest dose achieving normal liver fat levels. Those numbers exceed anything reported for single or dual agonists in comparable trials. The glucagon receptor component appears to be the differentiator, directly stimulating hepatic fatty acid oxidation in ways that GLP-1 alone does not. This article covers what the clinical data actually shows, what it does not, and where retatrutide fits in the broader MASH treatment pipeline. For context on how MASH became a target for peptide therapies, see Semaglutide for Liver Fat.
Key Takeaways
- Retatrutide 12 mg reduced liver fat by 86% at 48 weeks, with 93% of participants achieving normal liver fat below 5%, versus 0% on placebo (Sanyal et al., Nature Medicine, 2024)
- Liver fat reduction was dose-dependent: -51.3% at 1 mg, -59.0% at 4 mg, -81.7% at 8 mg, and -86.0% at 12 mg at 48 weeks (Sanyal et al., 2024)
- Beta-hydroxybutyrate levels increased 2-3 fold with retatrutide doses of 4 mg and above, suggesting the glucagon component drives hepatic fatty acid oxidation
- In the parent obesity trial, retatrutide 12 mg produced 24.2% body weight loss at 48 weeks, the largest reduction reported for any anti-obesity peptide at the time (Jastreboff et al., NEJM, 2023)
- Fibrosis data is limited: only 7.1% of MASLD substudy participants had markers suggesting significant fibrosis at baseline
- For comparison, tirzepatide (dual agonist, no glucagon) achieved MASH resolution in 62% of patients with confirmed F2-F3 fibrosis at 52 weeks (Loomba et al., NEJM, 2024)
What Is Retatrutide?
Retatrutide (LY3437943) is Eli Lilly's investigational triple agonist peptide that activates three receptors: the glucagon-like peptide 1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This makes it structurally and mechanistically distinct from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). The addition of glucagon receptor agonism is what separates retatrutide from its predecessors and appears to be the key to its liver effects.
Rosenstock et al. (2023) established retatrutide's metabolic profile in a phase 2 trial involving people with type 2 diabetes.[4] The drug improved glycemic control (HbA1c reductions) and produced substantial weight loss, with a safety profile consistent with GLP-1 receptor agonists. This trial provided the clinical foundation for investigating retatrutide in metabolic liver disease.
The Liver Fat Data: Phase 2a Results
The pivotal liver data comes from Sanyal et al. (2024), published in Nature Medicine.[1] This was a substudy of the phase 2 obesity trial, specifically enrolling 98 participants who had metabolic dysfunction-associated steatotic liver disease (MASLD) and at least 10% liver fat at baseline.
Design: Randomized, double-blind, placebo-controlled. Participants received weekly subcutaneous retatrutide (1, 4, 8, or 12 mg) or placebo for 48 weeks.
24-week results
Mean relative change from baseline in liver fat:
- Placebo: +0.3%
- 1 mg: -42.9%
- 4 mg: -57.0%
- 8 mg: -81.4%
- 12 mg: -82.4%
All retatrutide groups were statistically significant versus placebo (P < 0.001).
Percentage achieving normal liver fat (below 5%):
- Placebo: 0%
- 1 mg: 27%
- 4 mg: 52%
- 8 mg: 79%
- 12 mg: 86%
48-week results
Mean relative liver fat change from baseline:
- Placebo: -4.6%
- 1 mg: -51.3%
- 4 mg: -59.0%
- 8 mg: -81.7%
- 12 mg: -86.0%
Percentage achieving normal liver fat:
- Placebo: 0%
- 1 mg: 57%
- 4 mg: 29% (lower than 24-week value; likely reflects small sample variability)
- 8 mg: 89%
- 12 mg: 93%
The dose-response relationship is clear: higher doses produced greater liver fat reduction, with the most substantial effects at 8 mg and 12 mg. Most of the liver fat reduction occurred by week 24, with modest additional improvement from weeks 24 to 48 at higher doses.
Why the Glucagon Component Matters
The liver fat reductions with retatrutide exceed those reported for GLP-1 mono-agonists or GLP-1/GIP dual agonists at similar timepoints. The Sanyal et al. paper attributes this difference to glucagon receptor agonism acting directly on the liver.
Glucagon's hepatic effects include:
- Stimulating fatty acid oxidation: Glucagon activates hormone-sensitive lipase through cAMP/PKA signaling, promoting breakdown of stored triglycerides in liver cells. Glucagon binds to its receptor on hepatocytes, triggering a cascade that increases mitochondrial beta-oxidation of fatty acids.
- Reducing lipogenesis: Glucagon suppresses the de novo synthesis of fatty acids in the liver by inhibiting acetyl-CoA carboxylase, the rate-limiting enzyme in fat synthesis. This dual action (burning more fat while making less) creates a net negative fat balance in the liver.
- Increasing ketogenesis: Beta-hydroxybutyrate, a ketone body produced when fatty acids are oxidized, increased 2-3 fold in retatrutide-treated participants at doses of 4 mg and above. The largest increases occurred by week 24, coinciding with the period of most rapid liver fat reduction.[1]
- Reducing hepatic lipoprotein secretion: Glucagon receptor signaling decreases VLDL secretion from the liver, reducing the amount of triglyceride-rich particles released into the bloodstream.
This metabolic signature suggests that retatrutide does not reduce liver fat solely through weight loss. The glucagon component appears to directly shift hepatic metabolism toward fat oxidation. Whether this translates to better outcomes in advanced liver disease remains unproven.
The theoretical concern with glucagon agonism is hyperglycemia: glucagon stimulates hepatic glucose output. In retatrutide, the GLP-1 and GIP agonist components counterbalance this effect by enhancing insulin secretion and suppressing glucagon release from alpha cells. Rosenstock et al. (2023) showed that retatrutide improved glycemic control in people with type 2 diabetes despite the glucagon component, confirming that the three-receptor combination produces net metabolic benefit.[4]
How Retatrutide Compares to Other Peptides
vs. Tirzepatide (GLP-1 + GIP)
Loomba et al. (2024) published the SYNERGY-NASH trial, a phase 2 study of tirzepatide in participants with biopsy-confirmed MASH and moderate to severe fibrosis (F2-F3).[3]
At 52 weeks, MASH resolution without worsening of fibrosis:
- Placebo: 10%
- Tirzepatide 5 mg: 44%
- Tirzepatide 10 mg: 56%
- Tirzepatide 15 mg: 62%
Fibrosis improvement of at least one stage without MASH worsening:
- Placebo: 30%
- Tirzepatide 5 mg: 55%
- Tirzepatide 10 mg: 51%
- Tirzepatide 15 mg: 51%
Direct comparison between retatrutide and tirzepatide liver data is not straightforward. The SYNERGY-NASH trial enrolled participants with biopsy-confirmed MASH and F2-F3 fibrosis, a sicker population than the retatrutide substudy. The retatrutide trial measured liver fat by MRI-PDFF (a non-invasive imaging marker), while SYNERGY-NASH used liver biopsy as the primary endpoint. These are fundamentally different measures.
vs. Semaglutide (GLP-1 only)
Semaglutide has demonstrated meaningful liver fat reduction in multiple trials, but its effects appear smaller in magnitude than retatrutide's at comparable timepoints. Semaglutide lacks both the GIP and glucagon receptor activity that may contribute to retatrutide's more pronounced hepatic effects. The survodutide program (GLP-1 + glucagon, without GIP) provides another comparator, as it isolates the glucagon contribution from the GIP component.
The Weight Loss Context
Retatrutide's liver effects cannot be separated from its weight loss effects. Jastreboff et al. (2023) reported the parent obesity trial data: 24.2% mean body weight reduction at 48 weeks with retatrutide 12 mg, versus 2.1% with placebo.[2]
At 48 weeks with 12 mg:
- 100% of participants lost at least 5% of body weight
- 93% lost at least 10%
- 83% lost at least 15%
The 338-participant trial enrolled adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. 51.8% were men. Adverse events were predominantly gastrointestinal (nausea, diarrhea, vomiting), dose-related, mostly mild to moderate, and partially mitigated by starting at 2 mg rather than 4 mg. Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.[2]
The Sanyal et al. analysis found that liver fat reductions were "significantly related to changes in body weight, abdominal fat and metabolic measures associated with improved insulin sensitivity and lipid metabolism."[1] This means weight loss contributes to the liver fat reduction, but the beta-hydroxybutyrate data suggests an independent hepatic mechanism on top of the weight-mediated effect. Disentangling the weight-dependent from weight-independent liver effects will require dedicated mechanistic studies, ideally comparing retatrutide to a dual agonist producing equivalent weight loss.
What the Data Does Not Show
Fibrosis improvement is unproven
The article's title references fibrosis, but the retatrutide MASLD substudy provides limited fibrosis data. Mean baseline FIB-4 index ranged from 0.7 to 0.9 across groups, and mean baseline ELF score ranged from 7.8 to 8.3. Only 7 participants (7.1%) had either a FIB-4 index above 1.3 or an ELF score above 9.8, thresholds suggesting clinically meaningful fibrosis.[1]
This means most participants likely had simple steatosis or MASH with mild fibrosis. The study was not designed or powered to assess fibrosis regression. Sanyal et al. explicitly stated that the results should be considered "hypothesis-generating and not definitive" regarding fibrosis.
No biopsy data
Unlike the tirzepatide SYNERGY-NASH trial, the retatrutide substudy did not include liver biopsies. Liver fat was measured by MRI-PDFF, which accurately quantifies steatosis but cannot assess inflammation, hepatocyte ballooning, or fibrosis staging. These are the histological features that define MASH and determine disease severity.
Small sample size
With 98 participants split across 5 groups, each dose arm contained roughly 20 people. This is standard for a phase 2a substudy but provides limited power to detect differences in secondary endpoints or to identify rare adverse events.
No long-term data
48 weeks of treatment provides meaningful short-term efficacy data, but MASH is a chronic disease that progresses over years to decades. Whether liver fat reduction with retatrutide translates to prevention of cirrhosis, liver failure, or hepatocellular carcinoma is unknown.
Where Retatrutide Goes Next
Eli Lilly has initiated phase 3 trials for retatrutide in MASH (NCT05931367). These trials will include liver biopsy endpoints, larger sample sizes, and longer treatment durations. Results are expected to clarify whether the dramatic liver fat reductions seen in phase 2a translate to histological improvement in patients with established fibrosis.
The competitive landscape is intense. Resmetirom (Rezdiffra) received FDA approval for MASH with fibrosis in March 2024, becoming the first approved drug for this indication. Tirzepatide's SYNERGY-NASH data is strong. Survodutide (Boehringer Ingelheim's GLP-1/glucagon dual agonist) and pemvidutide (Altimmune) are also in late-stage development.
Retatrutide's advantage is the combination of three receptor targets in one molecule, potentially addressing liver fat (glucagon), appetite (GLP-1), and insulin sensitivity (GIP) simultaneously. Whether that translates to superior clinical outcomes over dual agonists or approved therapies remains the open question.
The Bottom Line
Retatrutide produced the largest liver fat reductions reported for any peptide-based therapy in a phase 2a substudy, with up to 86% relative reduction and 93% of participants achieving normal liver fat at 48 weeks. The glucagon receptor component appears to drive direct hepatic fat oxidation beyond what weight loss alone would explain. The data is limited by small sample size (n=98), lack of liver biopsy endpoints, and a population with mostly mild fibrosis. Phase 3 trials with biopsy-confirmed MASH and fibrosis staging are underway.